Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-19
DOI
10.1111/bjh.16881
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide
- (2019) Kazuyo Yamamoto et al. IMMUNOLOGY LETTERS
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
- (2018) Laurens E. Franssen et al. HAEMATOLOGICA
- Immunopathogenesis and immunotherapy of multiple myeloma
- (2018) Hideto Tamura INTERNATIONAL JOURNAL OF HEMATOLOGY
- Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
- (2018) Donatella Aldinucci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
- (2018) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
- (2018) Laurens E. Franssen et al. HAEMATOLOGICA
- Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
- (2018) Viktor Fleming et al. Frontiers in Immunology
- Homo-PROTACs for the Chemical Knockdown of Cereblon
- (2018) Christian Steinebach et al. ACS Chemical Biology
- Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
- (2017) Manh-Cuong Vo et al. EXPERIMENTAL HEMATOLOGY
- Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
- (2017) Chrissy H.Y. van Beurden-Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
- (2017) Federica Costa et al. Oncotarget
- IRF-8 regulates expansion of myeloid-derived suppressor cells and Foxp3+ regulatory T cells and modulates Th2 immune responses to gastrointestinal nematode infection
- (2017) Rajesh M. Valanparambil et al. PLoS Pathogens
- Myeloid-derived suppressor cells: The green light for myeloma immune escape
- (2016) Ehsan Malek et al. BLOOD REVIEWS
- Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
- (2016) Sung-Eun Lee et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma
- (2016) Sarah Maria Johler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response
- (2016) Yuhuan Zheng et al. JNCI-Journal of the National Cancer Institute
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion
- (2016) Balint Otvos et al. STEM CELLS
- Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response
- (2016) Yuhuan Zheng et al. JNCI-Journal of the National Cancer Institute
- Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer
- (2015) S. Takeuchi et al. CANCER RESEARCH
- Regulation of myelopoiesis by the transcription factor IRF8
- (2015) Tomohiko Tamura et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
- (2015) K. Yaddanapudi et al. Cancer Immunology Research
- Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
- (2014) Brenda De Keersmaecker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-induced CD14+HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients
- (2014) Zhitao Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
- (2014) A. Busch et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma
- (2014) James Favaloro et al. LEUKEMIA & LYMPHOMA
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
- (2013) G. T. Gorgun et al. BLOOD
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
- (2010) Joris D Veltman et al. BMC CANCER
- The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients
- (2010) Yanran Cao et al. EXPERIMENTAL HEMATOLOGY
- Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways
- (2010) T Kobayashi et al. LEUKEMIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started